tickstock newsroom AI
Articles
Shield Therapeutics reports 54% growth in ACCRUFeR sales, but warns over impact of Medicaid changes
Shield Therapeutics reported Q1 2026 net revenue of $18m and positive EBIT of c.$2.5m, driven by a $7.9m development milestone and 54% growth in its ACCRUFeR® franchise.
The Premarket Brief: AstraZeneca, Pearson, NatWest, Santander UK, Lansdowne Oil & Gas, Total Graphite, Active Energy Group, Union Jack Oil, accesso Technology Group
Total Graphite to update Montepuez DFS and VES as it reworks project economics
Active Energy to raise £1.3m to fund Middle East digital-asset infrastructure
Santander UK completes £2.86bn cash acquisition of TSB
NatWest raises 2026 income guidance to top end of range after strong Q1
NatWest Group now expects 2026 income to be at the top end of its previously guided £17.2-17.6bn range, citing its latest interest rate and economic assumptions.
ProService flags FY26 revenue miss as Speedy Hire ramp-up lags
TEAM completes EPIC Guernsey takeover
Union Jack Oil says Crossroads spud delayed as rig remains under maintenance
Union Jack Oil's planned spud of the Crossroads Well in southern Oklahoma has been postponed while the rig undergoes maintenance, with a spud date to be provided in early May.
accesso appoints Lee Cowie as its new CEO
accesso Technology Group has appointed Lee Cowie as Chief Executive Officer with effect from 1 May, and Steve Brown has stepped down as Chief Executive Officer and as a Director while remaining available to the Board during a handover.
AstraZeneca's Truqap recommended by FDA advisory panel for a form of prostate cancer
The FDA panel agreed that Truqap (capivasertib) plus abiraterone and ADT has a favourable benefit‑risk profile for a form of prostate cancer.
AstraZeneca fails to win FDA advisory backing for camizestrant
An FDA Oncologic Drugs Advisory Committee voted 3-6 and did not reach a majority in favour of the benefit-risk profile for camizestrant combined with a CDK4/6 inhibitor in first-line HR-positive, HER2‑negative advanced breast cancer.
Mining Today: South32, Ajax Resources, New Frontier, First Tin, Alba, Kefi, Glencore, Blencowe, Iofina, Kazera
Tech Today: Built Cybernetics, Visum, Weir Group, Sage, ZOO Digital
A dilutive fundraise hammers Built Cybernetics to the bottom of the leaderboard, while a broad sweep of trading updates and strategic pivots keeps the session busy across tech and tech-adjacent names. Elsewhere, a modular edge AI repositioning from Visum.
Deutsche Bank downgrades Haleon, cautions over lack of innovation
Jet2 downgraded as DB accounts for softening demand since start of Iran conflict
Panmure Liberum eyes 'strategic pivot' at BUY rated Whitbread
Panmure Liberum rates Whitbread BUY with a 3,440p price target after the Premier Inn owner extended its five‑year plan to FY31 and flagged a full exit from branded restaurants plus additional sale‑and‑leasebacks.
Persimmon is building momentum despite tough market says analyst
Persimmon's early‑2026 sales and order‑book gains underpin maintained completion guidance and support current profit expectations.
Are retail investors losing interest in ESG?
Tara Irwin, senior ESG analyst at Hargreaves Lansdown, says a December 2025 survey finds retail prioritisation of climate falling even as expectations of institutional action and scrutiny of banks rise.
The ECB has left the door open for a June hike
Mark Wall, Chief European Economist at Deutsche Bank, says that although the ECB left policy rates unchanged there are symmetric upside risks to inflation and downside risks to growth, keeping the option of a June increase alive.